helping reduce the symptoms of cystic fibrosis. However, these medications are only effective in people with specific CFTR mutations. Therefore, doctors will choose the type of CTFR modulator ...

Cystic fibrosis (CF) is a life-threatening genetic ... a condition affecting up to 50% of adults with CF. CF is caused by ...

ReCode Therapeutics is set to secure up to $15m in additional funding from the Cystic Fibrosis Foundation ... stemming from mutations in the CFTR gene. The company’s lead programmes, RCT2100 ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

CFTR mutations lead to CF by causing CFTR protein ... is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one copy ...

ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not ... of people living with cystic fibrosis,” said Reshma ...

The medicine, called trikafta, can treat cystic fibrosis patients who have at ... With this approval, 94 additional non-F508del CFTR mutations have been added to the trikafta label, making about ...

Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK "This ...

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ... including 31 additional mutations not responsive to other ...